ADC Therapeutics SA (ADCT) Tops Q2 EPS by 14c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.25), $0.14 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $18.84 million versus the consensus estimate of $18.05 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Lowe's slashes full-year sales outlook amid DIY spending pressure